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Purpose: Endothelial dysfunction is a known comorbidity in women with polycystic
ovary syndrome (PCOS). The aim was to assess if supervised, moderate intensity
exercise could potentially impact markers of endothelial disruption; endothelial cell
derived microparticles (EMP).
Methods: The current study investigated the effects of a supervised 8-week moderate
intensity exercise programme on EMP in women with PCOS (n= 11) and control women
free from any known disease (n = 10). EMP were enumerated via specific antibody
(CD105, CD106) labeling and flow cytometry.
Results: CD105+MP significantly reduced in women with PCOS from pre to
post-exercise programme, with CD105+ MP reducing from 2114 CD105+ MP
per µl platelet free plasma (PFP) to 424 CD105+ MP per µl PFP (p = 0.025).
Control women showed no significant change in CD105+ MP (p = 0.25) after
completing the same exercise programme. CD106+ MP showed no change in either
PCOS (p = 0.95) or control groups (p = 0.99). No significant correlations existed
with the changes in EMP compared to body composition changes as a result
of exercise.
Conclusion: Supervised, moderate intensity exercise independent of substantial weight
loss reduced circulating CD105+ MP, likely reflecting an improvement in endothelial
function in women with PCOS compared to healthy control women. Additionally,
EMP may be a useful marker for physical improvement in exercise programmes for
clinical populations.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in women of reproductive age (1)
and can account for up to 18% of the population depending
on the diagnostic criteria used (2–4). PCOS represents a
significant burden on the healthcare system due to its exhaustive
list of related complications (2). Women with PCOS are
known to have increased intrinsic insulin resistance (IR) when
compared with non-PCOS women, independent of obesity
(1, 5). PCOS is also known to increase the prevalence and
risk of cardiovascular disorders including hypertension and
dyslipidemia and infertility (4, 6). Furthermore, it is noted that
between 40 to 60% of PCOS women are either overweight [body
mass index (BMI) > 25 kg.m2] or obese (BMI > 30 kg.m2)
with increased central adiposity (7). The main risk factors for
development of PCOS manifest as atypical precocious puberty,
premature pubarche, obesity, and metabolic syndromes in
childhood (8, 9).
One abnormality that presents in PCOS women is endothelial
dysfunction (ED) the underlying mechanism of which remains
unclear but may be related to the hypertension and dyslipidemia
that is reported (10, 11). ED has been assessed using various
methods in women of this population, such as through flow-
mediated dilation (FMD) (12–15) and EndoPAT-2000 (16).
In addition a relationship between ED as measured by FMD
and insulin resistance was shown previously in children and
adolescents (17). Endothelial adhesion markers have also been
studied in PCOS women (10, 16, 18). Diamanti-Kandarakis et al.
(10) studied 25 women with PCOS and 25 women without PCOS
investigating ED by measuring endothelial activation markers,
as well as brachial artery FMD (BA-FMD). FMD values were
significantly lower in the PCOS group, as well as ET-1 levels. Also,
the PCOS group had higher levels of high sensitivity C-reactive
protein, soluble intercellular adhesion molcule-1 (sICAM-1)
and soluble CD106 (VCAM-1) compared to the control group,
suggesting that PCOS women do present with an abnormal
endothelial status, and endothelial adhesion markers can predict
this altered state. Given that PCOS is associated with an increased
cardiovascular disease (CVD) risk, and reduced endothelial
functioning increases this risk (18), the clinical importance
of lifestyle improvement on endothelial function in PCOS
needs investigation.
Incorporating exercise as a treatment for PCOS may be
favorable considering the benefits that exercise has in other
conditions that are associated with PCOS (19). Lifestyle
modification has been endorsed by the Androgen Excess and
PCOS Society as a primary choice in the prevention of CVD (4).
There are well-established benefits of exercise and weight loss
in women with PCOS on factors such as reproductive function
(20) and improvements in CVD risk markers such as obesity
and cardiorespiratory fitness (21), but there is limited data on
the effect of exercise on EF in women with PCOS (18). Exercise
training improves EF in individuals presenting with similar risk
factors to PCOS women, such as patients with type 2 diabetes
mellitus (22) and hypertension (23).
Endothelial microparticles (EMP) offer an insight into the
state of the endothelium and are known to be elevated in
diseases characterized by ED (24, 25). EMP have also been
shown to increase after exercise/endothelial stress in healthy
individuals (26, 27) but their characterization over a longer
period in response to exercise training in disease states associated
with ED remains relatively novel. Markers previously used
to identify EMP include CD105 (Endoglin), a constitutively
expressed endothelial cell marker and also markers of endothelial
cell activation such as CD106 (vascular cell adhesionmolecule-1).
Willis et al. (28) has previously shown an increased percentage
of Annexin V positive MP in the blood of women with PCOS
compared to controls, although EMP were noted as infrequent
using a CD144 antibody for detection.
We hypothesized that EMPs would be disordered in PCOS
reflecting the ED and that exercise may ameliorate those changes.
The aim of this study was to assess ED utilizing CD105+MP and
CD106+ MP in women with PCOS undergoing a supervised 8-
weekmoderate intensity exercise programme and control women
free from any known disease. The aim was to assess if this type
of exercise could improve EF in this population, and if there
was a relationship between EMP and other factors, such as body
composition and cardiorespiratory fitness.
PATIENTS AND METHODS
Outline
Favorable ethical opinion for the study was gained through the
NHS (LREC reference: 10/H1313/44). All of the participants
recruited for this study were aged between 18 and 40 years
of age. Pre-menopausal PCOS women were recruited who had
been outpatients at the Hull and East Yorkshire Diabetes,
Endocrinology and Metabolism Clinic in the past 5 years and
were eligible if they showed characteristics of PCOS as described
by the Rotterdam consensus (29). PCOS was diagnosed based
on the presence of oligomenorrhoea, clinical or biochemical
hyperandrogenism, and polycystic ovaries on ultrasound (after
exclusion of other endocrine causes of hyperandrogenism).
All non-PCOS women had regular menses and no evidence
of clinical or biochemical hyperandrogenism. Any volunteer
suffering from an existing medical condition that was defined
as a contraindication to exercise or injury was excluded from
the study. At each initial visit, participants were screened
via a pre-exercise medical questionnaire to highlight any
contraindications to the test protocol and written informed
consent was provided following successful completion of the
inclusion [aged 18–40, premenopausal women with PCOS (as
defined by Rotterdam consensus) and exclusion criteria (regular
exercise three times a week for last 3 months, pregnancy/breast
feeding/attempting to conceive, history of cardiovascular, renal,
hepatic and thyroid disease, history of diabetes mellitus,
history of physical disability to exercise, history of allergy to
insulin/soy oil/purified egg (intralipid), currently on oral anti-
diabetic medicine improving insulin sensitivity, family history
of sudden death]. BMI categories were defined as in the ACSM
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guidelines (2003) and those between 18.5 and 40.0 kg/m2
were eligible.
Participant Characteristics
Fourteen women with PCOS (mean ± SD, age 28.75 ± 6.61
years, BMI 30.70 ± 6.02 kg/m2) and 11 matched controls (age
23.74± 6.11 years, BMI 25.92± 5.39 kg/m2) volunteered for this
study and all gave written informed consent. All of these women
were successfully screened and eligible for entry into the study,
and they then began the 8-week exercise programme. The end
of the exercise programme was deemed as 8 successful weeks,
and subsequently the final assessment session occurred (post).
Only those participants who managed to successfully finish the
8-week exercise programme were included in the data analysis.
Participants were discontinued from the study if they became
pregnant, missed more than 50% (6 sessions) of exercise per
month, if the participant had to use any concomitant medications
detailed in the exclusion criteria during the study period, or
if her consultant physician or general practitioner requested
that the participant should be withdrawn from the study in
their best interest. Four women were unable to fully complete
the exercise programme and were not entered into the final
analysis as a result. Reasons for discontinuation of the study were
personal problems (2, both PCOS group), pregnancy (1, PCOS
group), and lack of attendance (1, non-PCOS group). The final
participants analyzed were those that successfully completed the
8-week exercise programme, which consisted of 21 women (11
PCOS (age 28.00 ± 6.72 years, BMI 31.15 ± 6.30 kg/m2) and
10 controls (age 24.26 ± 6.18 years, BMI 25.92 ± 5.39 kg/m2).
Glucose disposal rates were calculated as previously described
utilizing hyperinsulinaemic euglycaemic clamps (30) at baseline
and after completion of the programme.
Baseline Assessment
Eligible participants for the study attended the Michael White
Diabetes Center, Hull, UK within 1 week of the baseline
assessment visit (pre), which took place at the University
of Hull. At this initial visit, fasting venous blood samples
were taken and analyzed immediately for the measurement
of CD105+ MP and CD106+ MP. Within 1 week of this
visit, participants arrived at the University of Hull where
they completed a pre-exercise questionnaire. Participants were
instructed to abstain from alcohol, caffeine, and exercise 24 h
prior to the testing, and all baseline assessments took place
between 08:30 and 10:00 in order to maintain consistency
amongst participants and to reduce the effect of any circadian
variation in biomarkers, which have been shown to change over
a 24 h period (31). Once appropriate screening had taken place
and eligibility for the exercise programme had been confirmed,
anthropometric measures were recorded. Immediately after this,
participants performed a rampedmaximal exercise test (VO2max)
in order to determine the individuals target workload for the
exercise sessions.
Exercise Training Programme
Within a week following the baseline assessment, participants
began attending 3 supervised exercise sessions per week for
a period of 8 weeks. Where possible, each session was
1 h in duration depending on their ability to complete the
sessions with no complications. The programme used either
a Woodway ELG55 motorized treadmill (Woodway, Weil
am rhein, Germany), or a HP Cosmos Pulsar Treadmill
(H/P/Cosmos) with the same protocol. Participants performed
all sessions on a motorized treadmill working at or as closely as
possible to 60% VO2max. VO2/kg was measured after the warm
up, which lasted for 5min at 4.5 km.hr−1 and for a period of
10min in order to confirm the appropriate exercise intensity. The
intensity of exercise was then adjusted by altering the speed of
the treadmill if this value was not within ±2.5% of the target
oxygen uptake. Following this 10min gas collection, the facemask
was withdrawn with the speed of the treadmill remaining as it
was. A further gas collection was made at 40min to confirm
the desired intensity for a 5min period. If this intensity was
out of range then the treadmill speed was once again altered if
required. Heart rate (HR) and rate of perceived exertion (RPE)
(32) were monitored every 15min throughout the session. If
participants felt that they could not continue with the exercise
for reasons such as injury or fatigue, they were able to stop at
any time if necessary. Likewise, if it meant reducing the intensity
for a period of time in order for them to recover then this was
permitted, otherwise the intensity remained at the level pre-
determined. Each session ended with a 5min cool down at 4.5
km.h−1 and participants would then be free to leave once HR
returned to within 120% of basal levels. The participants in the
study were not asked to alter their diet in any way and were to
continue as normal with their calorie consumption throughout
the exercise programme. During exercise session visits, fluid
intake was permitted ad libitum.
Mid-Point Assessment
Participants performed an exact repeat of the baseline assessment
within 3 days after the 4 successful weeks of the exercise
programme had been completed. This mid-point assessment
also aided in altering the prescribed exercise intensity for the
exercise programme sessions thereafter if the individual managed
to improve their fitness over the 4 weeks of initial training.
Final Assessment
This final assessment at the end of the exercise programme
for each participant was a repeat of the baseline and mid-
point assessments.
Venous Blood Samples
Venous blood samples were drawn from the antecubital vein via
a standard venepuncture procedure into Vacuette blood tubes
(Vacuette R©, Greiner BIO-one, UK). Blood samples were taken no
longer than 1 week prior to baseline assessment (pre), then after
4 successful weeks of the exercise programme (mid), and again in
the final week nomore than 1 week after ceasing with the exercise
programme (post). Venous samples were all taken at or as closely
as possible to 09:00 h following an overnight fast.
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Endothelial Microparticles
Citrated blood was analyzed by obtaining platelet rich plasma
through centrifugation (180 g, 10min) using a Heraeus Labofuge
400R Centrifuge (Kendro Laboratory products, UK), which
was then removed carefully into a 1.5ml polypropylene tube.
Platelets were removed by further centrifugation (12,000 g,
10min) using a HeraeusBiofuge Pico Centrifuge (Kendro
Laboratory products). Subsequently, samples of platelet free
plasma (PFP) (25 µl) were incubated with 4 µl of either
IgG1 CD105:FITC conjugate (AbDSerotec, UK) or IgG1
CD106:FITC conjugate (AbDSerotec) in the dark at room
temperature for 30min. Quantification was achieved by
adding filtered phosphate buffered saline (150 µl PBS; 0.01M
phosphate buffer, 0.0027M KCl, 0.137M NaCl, pH 7.4 and
autoclaved; Sigma, UK) and Accucheck counting beads (25 µl,
Invitrogen, UK) immediately prior to analysis by flow cytometry
(BDFACSCalibur R©). A MP region (0.2–0.5µm, Figure 1A)
was set using megamix beads (Biocytex, France) according to
FIGURE 1 | Flow cytometry setup showing (A) MP and counting bead gate on
a forward scatter/side scatter plot with a side scatter threshold set according
to the megamix protocol and (B) typical antibody labeled MP events vs.
background/unlabeled events. MP are quantified using the counting beads.
an established protocol (33) and 25,000 events were counted
for MP analysis, with positive MP being defined as events
with an increased mean fluorescence intensity (Figure 1B),
and were quantified in relation to counting beads according to
manufacturers’ instructions.
Statistical Analysis
Central tendency and dispersion of the sample data are
represented as the mean ± SD. Any changes in biochemical
markers across condition and time were analyzed using linear
mixed models. The change in anthropometric measurements
across the exercise programme within the two populations were
investigated using paired samples t-tests with Sidak adjusted p-
values to control for family wise type I error rate. Relationships
between EMP and variables were analyzed using Pearson
Correlation Coefficients. Two-tailed statistical significance was
accepted at p < 0.05.
RESULTS
Baseline Characteristics
Table 1 displays the baseline characteristics of control and PCOS
women. There was a significant difference between the groups in
systolic blood pressure (SBP) (p = 0.027), which was higher in
the PCOS group. VO2max was significantly higher in the control
group (p < 0.001). Waist to hip ratio (WHR) (p = 0.019) and
waist circumference (WC) (p = 0.033) were significantly higher
in the PCOS group when compared to control women. Levels
of CD105+ MP were also significantly elevated in women with
PCOS (p= 0.021).
Effect of Exercise on Measured Variables
Table 2 displays the changes in biomarkers as a result of
the exercise programme in control and PCOS women. Body
TABLE 1 | Baseline characteristics between control and PCOS women.
Variables Control baseline PCOS baseline P-value
(n = 10) (n = 11)
Age (years) 24.26 ± 6.18 28.00 ± 6.72 0.202
Body mass (kg) 71.04 ± 16.42 85.45 ± 18.91 0.080
SBP (mmHg) 123.00 ± 11.44 132.36 ± 11.47 0.027a
DBP (mmHg) 77.50 ± 9.30 81.82 ± 11.21 0.290
VO2max
(ml.min−1.kg−1)
36.26 ± 6.38 26.32 ± 4.63 <0.001a
BMI (kg.m2) 25.92 ± 5.39 31.15 ± 6.30 0.056
WHR 0.79 ± 0.07 0.86 ± 0.06 0.019a
WC (cm) 83.01 ± 14.20 98.05 ± 16.35 0.033
Glucose disposal
(mg/kg min−1)
4.80 ± 1.73 3.26 ± 0.80 0.016
CD105 + MP
(per µl PFP)
388.2 ± 113.5 2,113.9 ± 951.7 0.021a
CD106 + MP
(per µl PFP)
7,165.1 ± 4403.8 7,625.6 ± 5,427.8 0.942
Body mass, SBP, DBP, VO2max , BMI, WHR, WC, CD105+ MP and CD106+ MP are
compared at baseline between the two groups.
aSignificantly different between groups (p < 0.05). All data represented as mean ± SD,
except for CD105+ MP and CD106+ MP which are represented as mean ± SEM.
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TABLE 2 | Clinical characteristics of the control and PCOS women at baseline, mid, and post 8 weeks of aerobic exercise training. Body mass, SBP, DBP, VO2max, BMI,
WHR and WC are compared between both groups.
Control (n = 10) PCOS (n = 11)
Variables Pre Mid Post Pre Mid Post
Body mass (kg) 71.04 ± 16.42 70.66 ± 16.19 70.11 ± 15.83 85.45 ± 18.91 84.45 ± 19.02a 84.04 ± 19.54a
SBP (mmHg) 123.00 ± 11.44 120.50 ± 10.28 117.50 ± 7.65a 132.36 ± 11.47 128.73 ± 11.03a 124.91± 10.40ab
DBP (mmHg) 77.50 ± 9.30 75.00 ± 6.82 73.10 ± 5.43 81.82 ± 11.21 81.36 ± 12.36 76.64 ± 8.82ab
VO2max (ml
.min−1.kg−1) 36.26 ± 6.38 37.49 ± 6.96 39.21 ± 5.82a 26.32 ± 4.63 26.43 ± 4.09 29.71 ± 5.32ab
BMI (kg.m2) 25.92 ± 5.39 25.78 ± 5.36 25.58 ± 5.18 31.15 ± 6.30 30.79 ± 6.32a 30.69 ± 6.48a
WHR 0.79 ± 0.07 0.78 ± 0.06 0.79 ± 0.07 0.86 ± 0.06 0.85 ± 0.07 0.85 ± 0.06
WC (cm) 83.01 ± 14.20 82.41 ± 14.19 82.16 ± 14.57 98.05 ± 16.35 96.97 ± 17.90 96.12 ± 14.67b
Data are represented as mean ± SD.
aSignificantly different compared to pre (p < 0.05).
bSignificantly different compared to mid (p < 0.05).
mass was unchanged in control women, but those with PCOS
managed to significantly reduce their body mass at mid exercise
programme (p = 0.027) and post-exercise programme (p =
0.027) when compared to pre exercise programme. Body mass in
PCOS women decreased from baseline from 85.45 kg to 84.45 kg
(−1.2%) at mid exercise, and then 84.04 kg (−1.7%) once the
exercise programme was completed. SBP improved pre to mid
(p = 0.031), pre to post (p = 0.002), and mid to post (p =
0.024) study in PCOS women. Diastolic blood pressure (DBP)
also improved pre to post (p= 0.020) andmid to post (p= 0.005)
study in this group. There were also improvements in VO2max
values from pre to post study, with values rising from 26.32 to
29.71 ml.min−1.kg−1 (p = 0.015) and also mid to post, from
26.43 to 29.71 ml.min−1.kg−1 (p = 0.002) in the PCOS group,
while BMI was improved from pre to post (p = 0.028) and pre
to mid (p = 0.015) point in the study. There was a decrease in
WC in this population from mid to post-exercise intervention,
decreasing from 96.97 to 96.12 cm (p= 0.035).
The control population only showed significant
improvements in SBP pre to post-intervention, decreasing
from 123 to 117.5 mmHg (p = 0.035) and VO2max pre to
post-intervention (36.26–39.21 ml.min−1.kg−1, respectively, p=
0.017). No other significant change was observed in any other
measured variable in this group.
CD105+ MP
EMP were enumerated by flow cytometry (Figure 1). The PCOS
group were the only group to see any significant changes
in blood variables (Figure 2), showing significant decreases
in CD105+ MP from pre to post-exercise intervention (p =
0.025). The number of MP decreased from 2114 CD105+
MP per µl PFP to 424 CD105+ MP per µl PFP. The
control group conversely showed little change over the exercise
programme, and no significant difference was observed pre to
post-intervention (p= 0.25).
CD106+ MP
There were no significant differences in CD106+ MP as a result
of exercise at any of the time points measured (Figure 3). The
PCOS group showed a very minimal decline from pre to post-
exercise intervention, with levels of CD106+ MP falling from
FIGURE 2 | CD105+ MP in control (dark bars) and PCOS (hatched bars)
participants at pre, mid, and post-exercise intervention. Data represented as
the concentration of CD105 + MP per µl PFP (means ± SEM). aSignificantly
different compared to pre in PCOS group (p = 0.025). Error bars represent
mean ± SEM.
7,626 to 7,210 CD106+ MP per µl PFP (p = 0.95). Similarly,
the control groups mean CD106+MP levels changed from 7,165
to 7,105 CD106+ MP pre to post-exercise intervention (p =
0.99). Interestingly, there was a decrease, albeit not significant,
in the control group from pre (7,165 CD106+ MP per µl PFP)
to mid exercise programme (2438.9 CD106+ MP per µl PFP,
p = 0.35), with values returning to basal values by the end of
the programme. There was also a slight decrease in the PCOS
group from pre to mid exercise programme, with CD106+
MP decreasing from 7,625 to 5,516 CD106+ MP per µl PFP
(p = 0.71), with values returning to basal values by the end of
the programme.
Correlations of Anthropometric Data With
EMP Data
Table 3 shows the correlations of CD105+MP and CD106+MP
with the variables measured throughout the exercise programme
in all PCOS women and control women. There were no
significant correlations with EMP data and any of the measured
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FIGURE 3 | CD106+ MP in control (dark bars) and PCOS (hatched bars)
participants at pre, mid, and post-exercise intervention. Data represented as
the concentration of CD106+ MP per µl PFP (means ± SEM). Error bars
represent mean ± SEM.
TABLE 3 | Correlation of CD105+ microparticles (MP) and CD106+ MP with
variables measured in control and PCOS participants throughout the entire
exercise programme from pre, mid to post 8 week intervention; r value determined
from Pearson’s Correlation Coefficient using group means ± SD, except for
CD105+ MP, and CD106+ MP (mean ± SEM).
Variable Control n = 10 PCOS n = 11
CD105+MP r-value P-value r-value P-value
Body mass (kg) −0.119 0.531 −0.041 0.822
SBP (mmHg) −0.067 0.724 0.303 0.092
DBP (mmHg) −0.050 0.794 0.193 0.289
VO2max (ml
.min−1.kg−1) 0.136 0.481 −0.094 0.613
BMI (kg.m2) −0.117 0.537 −0.008 0.966
WHR 0.027 0.891 −0.090 0.648
WC (cm) 0.051 0.789 0.125 0.528
CD106+ MP r-value P-value r-value P-value
Body mass (kg) −0.202 0.284 0.020 0.915
SBP (mmHg) −0.131 0.490 0.176 0.337
DBP (mmHg) −0.211 0.263 0.022 0.904
VO2max (ml
.min−1.kg−1) −0.014 0.944 0.114 0.543
BMI (kg.m2) −0.186 0.324 −0.017 0.929
WHR −0.236 0.218 −0.165 0.402
WC (cm) −0.249 0.185 −0.074 0.708
variables presented in Table 3 for either group, suggesting that
any changes in EMP were independent of these variables. The
strongest correlation occurred between SBP and CD105+ MP
in PCOS individuals, with suggestion that the higher the SBP
the greater the amount of CD105+ MP, but this was not
significant (p= 0.092).
Insulin Resistance
Glucose disposal rates (GDR) were calculated prior to and at
the completion of the programme and a significant overall trend
was observed with BMI (Figure 4) whereby the higher BMI was
associated with a lower GDR (r = 0.58, p= 0.006).
DISCUSSION
After an 8-week moderate intensity exercise programme women
with PCOS had significantly decreased levels of CD105+ MP
and improved GDR. This may indicate some improvement in
cellular health as a result of a short-term, supervised aerobic
exercise programme, independent of dietary modifications. An
additional finding of this study was that PCOS women displayed
significantly higher CD105+ MP at baseline when compared
to otherwise healthy, non-PCOS females (Table 1). CD105+
MP may be expected to be higher and associated with poor
endothelial function as CD105 (Endoglin) is a constitutively
expressed protein on the surface of all endothelial cells and
therefore would be expected to be present on all EMP released
whereas VCAM-1 (CD106) is a marker of activation. The data
suggests that there is no difference between the groups in
terms of endothelial cell activation but there is a significantly
higher amount of circulating CD105+ MP in the PCOS group.
The decrease in circulating CD105+ MP may be indicative of
an improvement in endothelial function. Previously Miniello
et al. (17) demonstrated a link between insulin resistance and
endothelial function and from our data here an improvement in
GDR was accompanied by a decrease in circulating CD105+MP.
This finding demonstrates that CD105+ MP may be a useful
marker of endothelial function, as others have also shown that
women with PCOS have endothelial dysfunction, using a variety
of different assessment methods, such as FMD (10, 15, 34) and
endothelial adhesion molecules (10). Furthermore, women with
PCOS significantly improved their metabolic risk, including body
mass, SBP, DBP, aerobic fitness, BMI and WC by the end of the
programme (Table 2).
The reduction in circulating CD105+ MP reported here for
the PCOS women may indicate accord with a study by Sprung
et al. (14) who found that EF (BA-FMD) was improved in women
with PCOS when compared to control women with PCOS who
received conventional care following a 16-week aerobic exercise
intervention. Ten women with PCOS underwent supervised
30min exercise 3 times a week at 30% heart rate reserve (HRR),
which progressed weekly based on HR responses (up to 60%
HRR). The control group received lifestyle advice from clinical
consultations prompting them to lose weight and increase their
physical activity. Various assessments were measured during the
study, including BA-FMD, cardiorespiratory fitness, visceral and
abdominal subcutaneous adipose tissue, glycaemic control, and
lipid and hormone profiles. When comparing the 2 groups, BA-
FMD and cardiorespiratory fitness improved from pre to post-
exercise intervention in the exercising group only, suggesting that
supervised aerobic exercise in women with PCOS can enhance
EF. Sprung et al. (14) however did not use women without
PCOS as controls, as it would also have also been useful to
see any differences between PCOS women and control women
without PCOS following the two interventions. Baseline body
composition data was similar between the two studies [BMI was
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FIGURE 4 | Relationship between glucose disposal rate and body mass in controls at baseline () and at final assessment () and women with PCOS at baseline
(•) and at final assessment (©).
31.1 kg.m2 in this study compared to 31 kg.m2 in (14); WC was
98.05 and 100 cm, respectively, whilst body mass was 85.45 kg
compared to 82.1 kg). However, despite not being statistically
significant there was an observed difference between body mass
and BMI reported here between the two groups, with the PCOS
group being higher in both assessments (Table 1). Also there is
potential for medication to impact EF within the PCOS group
however participants taking any oral anti-diabetic medicine to
insulin sensitivity or weight reduction medication were excluded
from the study. Comparatively to these findings, Roessler et al.
(35) investigated the effects of exercise and group counseling on
body composition and aerobic fitness in 17 women with PCOS.
WC, BMI, body mass and VO2max were improved in PCOS
women following a cross-over designed trial with the exercise
programme consisting of 3 sessions per week with 2 days of
indoor cycling and 1 day of brisk walking/running.
The exercise in Sprung et al. (14) was moderate in intensity,
although they used %HRR (30% HRR initially, rising to 60%
HRR) instead of %VO2max as in the present study (60% VO2max).
Initially, exercise was performed 3 times a week, as in the
present study, but for a period of just 30min, which was
then increased to 5 times per week up to 45min per session,
whereas a fixed protocol was adhered to in the present study.
Nonetheless, Sprung et al. (14) increased the length of their
sessions and frequency of training per week, presumably as
increases in fitness were observed in each group, similar to our
reassessing their mid-point fitness so that improvements in each
individual’s fitness could be used to re-evaluate the intensity for
the second half of the programme. These studies suggest that
supervised moderate aerobic exercise of 30–60min 3–5 days a
week is sufficient to improve EF and other CV risk factors,
such as WC, body mass and BP; however, changes in these
parameters did not correlate with EMP/EF. The changes in body
mass seen in the PCOS group were modest but significant from
pre to post-exercise intervention in the current study (85.45–
84.04 kg), suggesting that improvements in cardiorespiratory
fitness without substantial weight loss may reduce the CV risk
in women with PCOS, a finding also reported by others (14, 36).
Research assessing EF following exercise interventions in
PCOS women by endothelial biomarkers is very limited
(14). However, one study (18) looked at the effects of
exercise training on EF in PCOS women measuring circulating
biomarkers through a multiplex analyser (sCD106, sICAM-1)
and plasminogen activator inhibitor-1 (PAI-1). This study used 3
different groups, one group was a controlled diet with moderate
aerobic exercise (60–80% HRmax), one used diet combined with
aerobic-resistance training, and the other a diet only without
exercise. sCD106, sICAM-1, and PAI-1 all reduced at week 20
in each group compared to pre exercise programme, but the
parameters did not differ between groups.
Previous studies have shown that there was a significant
impairment in EF in PCOS women at baseline levels compared
to control women without PCOS (37–39). El-Kannishy et al.
(12) found that EF, as assessed by BA-FMD, was impaired in
both lean and obese women with PCOS. They assessed 22 obese
women with PCOS as well as 14 lean women with PCOS. Flow-
mediated dilation was significantly decreased in both groups of
women with PCOS. Further to this, it was found that FMD
was not correlated with BMI or IR. These findings suggest that
women with PCOS who are otherwise free of any other known
disease associated with PCOS still show characteristics of ED,
and therefore both lean and obese participants could still benefit
from an exercise intervention similar to that used in this study to
improve EF, even in the absence of other risk factors.
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A review of PCOS and exercise highlighted the various
limitations that are common in exercise interventions in women
with PCOS (2). Studies have generally been small in sample
size and have had a significant drop out rate (2). Based on the
verbal feedback provided throughout the study period, this high
compliance reported here was mainly due to the supervision
and monitoring of the exercise sessions, as well as the duration
and intensity of exercise sessions being favorable to participants,
and participants recruited were also highly motivated and
volunteered to take part. This leads to the suggestion perhaps
that a home based programme, at least in the early stages of an
intervention, may not be the best route to take, and that closely
monitored, supervised exercise interventions appear to have a
positive effect. Additionally, the effects of group based exercise
warrants future investigation given that social interaction may
be an exercise motive for some individuals to enable the social
element of group training. A further issue with existing literature
is that studies tend to use young womenwhowere predominantly
obese (2). This was one of the reasons for the inclusion of lean
women as well as obese in this study.
This study confirms that moderate intensity exercise (60%
VO2max) could be recommended for this population. The
data here also suggests that this type of moderate intensity
exercise is sufficient over a relatively short time frame to
see improvements in anthropometric measurements and a
reduction in circulating EMP. This is in agreement with other
studies who have also found improvements in women with
PCOS as a result of moderate intensity exercise (18, 40) but
future work could also investigate the use of incorporating
high intensity interval training or resistance training into an
exercise/diet programme in PCOS women which has previously
shown favorable results in body composition and aerobic
fitness (35).
There are several pharmaceutical interventions for PCOS,
which primarily focus on addressing reproductive dysfunction
and IR (2). However, lifestyle modification remains the first line
management to improve cardiovascular and reproductive risk
factors in women with PCOS (2, 41). The presented research
strengthens the idea that exercise should remain one of the first
line treatments for women with PCOS. EMP can be significantly
reduced following the prescription of moderate aerobic exercise
training, independent of any dietary restrictions.
CONCLUSION
CD105+ MP may be utilized as a circulating biomarker in
women with PCOS and a reduction in numbers following
an exercise programme is suggestive of an improvement in
endothelial cell health.
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